VJHemOnc is committed to improving our service to you

SOHO 2020 | Treating highly relapsed/refractory CLL

VJHemOnc is committed to improving our service to you

Michael Hallek

Michael Hallek, MD, of the University Hospital of Cologne, Cologne, Germany, outlines treatment options for relapsed/refractory patients with chronic lymphocytic leukemia and highlights the potential benefit of CAR T-cell therapies for these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter